warm to touch/the lesion was warm to the touch; It is very inflamed and not indurated/quite inflamed /local inflammatory response, perhaps with an IgE component (reflected in pruritus); itchy/initially pruritic /local inflammatory response, perhaps with an IgE component (reflected in pruritus); quite tender; cutaneous eruption surrounding site of inoculation/well circumscribed eruption/got a defined border; red; typically achy arm at first; This spontaneous case was reported by a physician and describes the occurrence of PAIN IN EXTREMITY (typically achy arm at first), VACCINATION SITE WARMTH (warm to touch/the lesion was warm to the touch), VACCINATION SITE INFLAMMATION (It is very inflamed and not indurated/quite inflamed /local inflammatory response, perhaps with an IgE component (reflected in pruritus)), VACCINATION SITE PRURITUS (itchy/initially pruritic /local inflammatory response, perhaps with an IgE component (reflected in pruritus)) and VACCINATION SITE PAIN (quite tender) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Multiple sclerosis since 1996. Concomitant products included RITUXIMAB (RITUXAN) for Multiple sclerosis, DOXYCYCLINE (ORACEA [DOXYCYCLINE]) from 2011 to an unknown date for Rosacea, MULTIVITAMIN [VITAMINS NOS] for an unknown indication.   On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Jun-2021, the patient experienced PAIN IN EXTREMITY (typically achy arm at first). On 04-Jun-2021, the patient experienced VACCINATION SITE WARMTH (warm to touch/the lesion was warm to the touch), VACCINATION SITE INFLAMMATION (It is very inflamed and not indurated/quite inflamed /local inflammatory response, perhaps with an IgE component (reflected in pruritus)), VACCINATION SITE PRURITUS (itchy/initially pruritic /local inflammatory response, perhaps with an IgE component (reflected in pruritus)), VACCINATION SITE PAIN (quite tender), VACCINATION SITE RASH (cutaneous eruption surrounding site of inoculation/well circumscribed eruption/got a defined border) and VACCINATION SITE ERYTHEMA (red). The patient was treated with IBUPROFEN ongoing since an unknown date for Adverse event, at a dose of 1 dosage form. At the time of the report, PAIN IN EXTREMITY (typically achy arm at first), VACCINATION SITE WARMTH (warm to touch/the lesion was warm to the touch), VACCINATION SITE INFLAMMATION (It is very inflamed and not indurated/quite inflamed /local inflammatory response, perhaps with an IgE component (reflected in pruritus)), VACCINATION SITE PRURITUS (itchy/initially pruritic /local inflammatory response, perhaps with an IgE component (reflected in pruritus)), VACCINATION SITE PAIN (quite tender), VACCINATION SITE RASH (cutaneous eruption surrounding site of inoculation/well circumscribed eruption/got a defined border) and VACCINATION SITE ERYTHEMA (red) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient reported developing a rash that was 13 centimeters down the left arm and 3 centimeters across. The patient stated that the itchiness has diminished somewhat, but that the warmth, redness, tenderness and defined border are ongoing.   Most recent FOLLOW-UP information incorporated above includes: On 07-Jun-2021: Follow-up received and No New Information. On 30-Jun-2021: significant followup added to include new events